Chromosome abnormalities detected by current prenatal screening and noninvasive prenatal testing

Obstetrics and Gynecology

Volumn 124, Issue 5, 2014, Pages 979-986

  Norton, Mary E ^a   Jelliffe Pawlowski, Laura L ^a   Currier, Robert J ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; AMNIOCENTESIS; ANEUPLOIDY; ARTICLE; CHROMOSOME ABERRATION; DISABILITY; DISEASE ASSOCIATION; DOWN SYNDROME; ETHNICITY; FEMALE; HIGH RISK POPULATION; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MATERNAL AGE; NEURAL TUBE DEFECT; NONINVASIVE PRENATAL TESTING; PREGNANT WOMAN; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; RACE; SMITH LEMLI OPITZ SYNDROME; TRISOMY 13; TRISOMY 16; TRISOMY 18; TRISOMY 21; AGE; BLOOD; CHROMOSOME DISORDERS; ECHOGRAPHY; EVALUATION STUDY; GENETIC SCREENING; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES; UNITED STATES;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; CALIFORNIA; CHROMOSOME DISORDERS; FEMALE; GENETIC TESTING; HUMANS; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 84925581764     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000452     Document Type: Article

References (29)

1. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-11.
2. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104.
3. Wapner RJ, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003;349:1405-13.
4. Invasive prenatal testing for aneuploidy. ACOG Practice Bulletin No. 88. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;110:1459-67.
5. Alfirevic Z, Mujezinovic F, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. The Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.: CD003252. DOI: 10.1002/14651858. CD003252.
6. Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP. Revisiting the fetal loss rate after genetic amniocentesis. Obstet Gynecol 2008;111:589-95.
7. Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y, et al. Pregnancy loss rates after amniocentesis. Obstet Gynecol 2006;108:1067-72.
8. Caughey AB, Hopkins LM, Norton ME. Chorionic villus sampling compared with amniocentesis and the difference in the rate of pregnancy loss. Obstet Gynecol 2006;108:612-6.
9. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20.
10. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;120:957.
11. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206:322.e1-5.
12. Sparks AB, Struble CA, Wang ET, Song K, Oliphant A. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206:319.e1-9.
13. Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;207:137.e1-8.
14. Benn P, Borell A, Chiu R, Cuckle H, Dugoff L, Faas B. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013;33:622-9.
15. Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:1532-4.
16. Wilson KL, Czerwinski JL, Hoskovec JM, Noblin SJ, Sullivan CM, Harbison A. NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy. J Genet Couns 2013;22:4-15.
17. Alamillo CM, Krantz D, Evans M, Fiddler M, Pergament E. Nearly a third of abnormalities found after first-trimester screening are different than expected: 10-year experience from a single center. Prenat Diagn 2013;33:251-6.
18. Wellesley D, Dolk H, Boyd PA, Greenlees R, Haeusler M, Nelen V. Rare chromosome abnormalities, prevalence and prenatal diagnosis rates from population-based congenital anomaly registers in Europe. Eur J Hum Genet 2012;20:521-6.
19. Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2012;14:296-305.
20. Currier R, Wu N, Van Meter K, Goldman S, Lorey F, Flessel M. Integrated and first trimester prenatal screening in California: program implementation and patient choice for follow-up services. Prenat Diagn 2012;32:1077-83.
21. Palomaki GE, Bradley LA, Knight GJ, Craig WY, Haddow JE. Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndrome. J Med Screen 2002;9:43-4.
22. Nussbaum RL, McInnes RR, Willard HF, editors. Thompson and Thompson genetics in medicine. 6th ed. Philadelphia (PA): WB Saunders Co; 2001. p. 140.
23. Chetty S, Garabedian MJ, Norton ME. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013;33:542-6.
24. Friel LA, Czerwinski JL, Singletary CN. The impact of noninvasive prenatal testing on the practice of maternal-fetal medicine. Am J Perinatol 2013 Dec. 11 [Epub ahead of print].
25. Gregg AR, Gross SJ, Best RG, Monaghan KG, Bajaj K, Skotko BG. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013;15:395-8.
26. Grati FR, Barlocco A, Grimi B, Milani S, Frascoli G, Di Meco AM, et al. Chromosome abnormalities investigated by non-invasive prenatal testing account for approximately 50% of fetal unbalances associated with relevant clinical phenotypes. Am J Med Genet A 2010;152 A: 1434-42.
27. Forabosco A, Percesepe A, Santucci S. Incidence of non-agedependent chromosomal abnormalities: a population-based study on 88, 965 amniocenteses. Eur J Hum Genet 2009;17:897-903.
28. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012;207:374.e1-6.
29. Nicolaides KH, Syngelaki A, Gil MM, Quezada MS, Zinevich Y. Prenatal detection of fetal triploidy by cell-free DNA testing in maternal blood. Fetal Diagn Ther 2014;35:212-7.